FDA red and green lights: April 2026
Full US approval of Gilead’s Tecartus was the only positive decision last month.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
ESMO 2025 – Roche sticks it to its SERD rivals
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
